Identifying genetic factors affecting survival after blood and marrow transplants
Multi-ethnic high-throughput study to identify novel non-HLA genetic contributors to mortality after blood and marrow transplantation
This study is looking at how certain genes might affect survival after blood and marrow transplants, and it's for patients who have undergone this treatment to help find ways to improve their outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10891474 on NIH RePORTER |
What this research studies
This research investigates the genetic factors that contribute to mortality after blood and marrow transplantation (BMT), particularly focusing on non-HLA genetic variants. By analyzing genetic data from a diverse group of patients, the study aims to identify specific genetic markers that may influence survival rates post-transplant. The approach includes whole-exome sequencing and genome-wide association studies to uncover both common and rare genetic variants. The ultimate goal is to develop clinical-genomic models that can help predict patient outcomes and improve treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients undergoing blood and marrow transplantation, particularly those from diverse ethnic backgrounds.
Not a fit: Patients who are not undergoing blood and marrow transplantation or those with conditions unrelated to hematologic diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates for patients undergoing blood and marrow transplants by identifying genetic risks and tailoring treatments accordingly.
How similar studies have performed: Previous studies have shown success in identifying genetic contributors to transplant outcomes, suggesting that this approach has the potential for meaningful advancements.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Hahn, Theresa E — Roswell Park Cancer Institute Corp
- Study coordinator: Hahn, Theresa E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.